This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
SUMMARY: The media loves to blame pharma companies for high healthcare costs, but unless we start to invest in healthy lifestyles, we’re headed for a healthcare crisis the likes of which we have never experienced. This means higher healthcare costs. has the potential to tax our already burdened healthcare infrastructure.
Greater collaboration among healthcare providers, medical device manufacturers, and lawmakers and regulators will lead to predictability and consistency in cybersecurity management. Together, we can make even greater strides toward patient safety and a more secure and sustainable healthcare system.
works to pump fresh cash into the local biopharma scene, London’s Accord Healthcare is capitalizing on the government’s renewed willingness to chip in. Accord—one of Europe's top makers of generic chemotherapies—is embarking on an expansion of its Fawdon drug manufacturing facility in Newcastle upon Tyne, England. As the U.K.
The metaverse holds promising potential to transform healthcare delivery for the better, according to a keynote talk delivered at MedCity’s Invest Digital Health conference. The speaker identified workforce training, patient experience, healthcare facilities and medical manufacturing as the main areas poised for disruption.
healthcare system is bedeviled by greed, with drug companies, device manufacturers, hospital organizations, physician groups, and insurers scrambling to grab a slice of the more than $3 trillion we spend on medical care each year. The bifurcation within our healthcare system is poised to get worse. (FT.COM) The U.S.
And to stop Americans from getting cheaper prescriptions, he is willing to sabotage American manufacturers (and therefore assist China) by denying them $52 billion in support under the U.S. There are also programs administered through state governments that can help with healthcare-related needs. The post Can we get healthcare right?
This is especially important when it comes to preventive healthcare. More precise and consumer-friendly biomarker detection technologies are coming to market at a pace that can help users gain rich insight into their health and well-being from anywhere and at any time.
Designing devices for re-use remains a more resilient solution for supply disruption in healthcare devices. But until manufacturers consistently pursue this strategy, single-use device reprocessing can provide the benefits associated with a circular economy solution.
To boost AstraZeneca’s research and manufacturing footprint by the end of 2026, it is dedicating $3.5 AstraZeneca’s investment in manufacturing In August, AstraZeneca announced its single biggest investment in its Sweden Biomanufacturing Center in Södertälje, since the facility opened in 2021. The post New $3.5b
The healthcare industry of the future will be defined by interoperable systems that need to securely share critical data across devices, distributed applications, and networks. Device manufacturers play a pivotal role in the delivery of these secure and connected solutions
Restructuring seems to be the name of the game for many large drugmakers these days, and Belgium-based UCB is no except | Belgium’s UCB is selling off its mature neurology and allergy business—plus a manufacturing plant—in mainland China.
This poses a significant challenge for pharmaceutical manufacturers, not least because of the technical challenges related to operations, supply chain and the environment. This article explores the potential impact of the proposal and considers how manufacturers can ensure the safety and reliability of their products.
FDA chided Kilitch Healthcare India for “poor practices” tied to written procedures around microbial contamination, shoddy lab records, behaviors that could have caused contamination and quality control lapses. In a four-observation warning letter issued this week, the U.S.
A veteran of GE Healthcare, Joe Gasque talks about how he's growing the company's niche position in the high-paced aesthetics industry, offering services to surgeons, practitioners, medical device and injectables manufacturers.
On a revised dealmaking spree this year, Korea’s Samsung Biologics is re-tooling its long-running drug manufacturing pact with Baxter Healthcare. | The revised deal, first established back in July of 2017, will now see Baxter pay Samsung upwards of $223 million for its manufacturing services through end of 2034.
In todays rapidly advancing healthcare landscape, the demands placed on medical professionals are greater than ever. Traditional approachestextbooks, live demonstrations, and hands-on workshopswhile valuable, are no longer sufficient to meet the complexities of modern healthcare. billion by 2025. billion by 2025.
The first good manufacturing practice (GMP) registration of a UK pharmaceutical facility for high Δ9-tetrahydrocannabinol (THC) cannabis active pharmaceutical ingredient (API) has been granted since the legalisation of medical cannabis in 2018. Thus, the MHRA’s approval supports improved regulation of medical cannabis manufacturing.
This media becomes especially important in healthcare since it enables the clear, concise, and efficient communication of difficult medical ideas, techniques, and patient education resources. Medical video production is producing excellent videos, especially for the demands of the pharmaceutical, medical device, and healthcare sectors.
AstraZeneca has announced it is expanding its current partnership with AI-based company G42 Healthcare, by signing an agreement to manufacture innovative drugs in Abu Dhabi, aligning with Abu Dhabi’s Industrial Strategy to double the size of its manufacturing sector by 2031. Manufacturing drugs in Abu Dhabi.
The UK will be the first country to introduce a tailored framework for the regulation of innovative medicines manufactured at the point where a patient receives care, the Medicines and Healthcare products Regulatory Agency (MHRA) has announced. Clear regulatory expectations and allowing easier product development.
Whether you represent a hospital, health system, or multilocation practice, competing healthcare businesses are developing innovative business models—right now—and they’re targeting your market. More businesses are developing with innovative ways to disrupt the status quo and drive competition in healthcare. The answer is twofold.
This week's podcast dives into successful sales leadership and is relevant to most healthcare verticals, including B2B sales in SaaS, pharmaceuticals, medical device, hospitals, etc. My guest, Chris Jennings , CEO of Chris Jennings Group , reveals the essential traits of successful healthcare sales leadership. Why Listen?
Incannex Healthcare has collaborated with New Jersey-based pharma company Catalent for the development and manufacturing of a cGMP-grade psilocybin drug product for clinical trials and potential commercial use. It will also establish cGMP manufacturing of a drug product which will be utilised in future clinical trials.
This programme was developed by the British Standards Institute (BSI) to verify companies that are taking the necessary steps in ensuring responsible antibiotic manufacturing in the global supply chain, helping to lower the spread of AMR.
Crucially, January 2023 marked a key moment: the Medicines and Healthcare products Regulatory Agency (MHRA) granted Celadon Pharmaceuticals the first good manufacturing practice (GMP) registration since legalisation in 2018 for high Δ9-tetrahydrocannabinol (THC) cannabis active pharmaceutical ingredient (API).
For the first time, companies across the global healthcare sector, including AstraZeneca , GSK, Novo Nordisk and Roche, have united to discuss with energy providers in China and India, about scaling renewable power across their supply chains. This step is important as these countries are key markets for pharmaceuticals manufacturing.
The Medicines Patent Pool (MPP) has signed sublicence agreements with three generics manufacturers to produce generic versions of cabotegravir long-acting (LA) injectable for human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP). The pharma companies who will manufacture the generic versions are Viatris, Aurobindo and Cipla.
Healthcare consumerism has drastically changed the way healthcare professionals need to market and deliver their services. Today’s consumers expect a healthcare experience as innovative and digitally advanced as any other industry. Think of all the reasons someone might decide to switch healthcare providers: . Relocation.
On 6 June 2023, the British Standards Institute (BSI) launched its Minimized Risk of Antimicrobial Resistance (AMR) certification for antibiotic manufacturing. Soulsby and Brooks explain what the new certification means for antibiotic manufacturers and the wider pharma industry, and its anticipated benefit for supply chain sustainability.
THE GLOBAL outbreak of the COVID-19 pandemic triggered an urgent need to protect people’s lives and livelihoods and the healthcare community recognised quite early that vaccines were the best solution to this crisis. Digital technologies for smart vaccine manufacturing. The future of platform-based vaccine technology and manufacturing.
The UK is set to be the first country to introduce a new regulatory framework for innovative products manufactured at or close to the point of patient care, says the Medicines and Healthcare products Regulatory Agency (MHRA). Products manufactured at the point of care are eligible for the MHRA ILAP pathway.
Healthcare consumers continue to move swiftly down the paths of least resistance toward quality care. This spells trouble for healthcare organizations that cannot change with the times. 9 Healthcare Marketing Trends 2023. 9 Healthcare Marketing Trends 2023. Consumer-First Content is Essential. Google is the gatekeeper.
Contract research, development and manufacturing organisation (CRDMO) WuXi STA has broken ground on its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware, US. WuXi STA has 12 sites across the US, Europe and Asia. The biopharmaceutical industry is part of Delaware’s DNA,” stated Delaware Governor John Carney.
A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 Data showed that worldwide, oral solids are the most popular mode of drug delivery due to being highly cost-effective and offering simple manufacturing processes.
On a mission to debut life science companies on the global stage, healthcare investment firm Great Point Partners is making a play for private German contract development and manufacturing organiza | On a mission to debut life science companies on the global stage, healthcare investment firm Great Point Partners is making a play for private German (..)
At Clalit, which is the second largest healthcare provider in the world, I worked in several management positions and gained a broad understanding of the needs and constraints of a healthcare system. I joined Pfizer in January 2023 as a health access specialist, after working at Clalit Health Services in Israel for almost 20 years.
Rising demand for therapeutics, especially in developing markets, is expected to expand the global pharmaceutical contract manufacturing market to $130.2 billion by 2026, as contract manufacturing organisations increasingly adopt newer and efficient ways to package products, increasing demand for new machinery. billion by 2026.
But scaling up production and ensuring global supply of sensitive biological pharmaceuticals is a remarkable process that embodies Industry 4.0 – the rapid technological advancement that is characterising the fourth industrial revolution – and the very latest in advanced manufacturing technologies.
With the money it costs us, the Government could encourage a private company to build a manufacturing facility for insulin while offering tax incentives. Dr. Jing Luo says the list price of insulin — the price set by manufacturers but not necessarily what patients or providers pay — has increased between 300% to 500%. billion to $5.7
More than $170 million of this spending was for products voluntarily withdrawn by their manufacturers after clinical trials showed that they did not improve overall survival in people with various types of cancer. This is another example of just how screwed up our healthcare system really is.
Conducted last month, survey respondents expect that tariffs will bring: A significant number of biotechs (94 percent) anticipate a surge in manufacturing costs if tariffs are put in place on import trade from the EU, thereby decreasing access to affordable medicines.
The Covid-19 pandemic pushed the healthcare industry toward rapid digitalisation, with the rise of telehealth, telepresence systems, remote diagnostics, predictive AI, and wearable technology now changing the way healthcare is delivered and improving patient outcomes.
Following Nucleus RadioPharma’s 2022 debut, the GE HealthCare- and Mayo Clinic-backed radiopharmaceuticals CDMO is ready to put its production thesis to the test. Nucleus on Tuesday revealed that it has signed its first manufacturing partnership with clinical-stage radiopharma player ARTBIO.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content